Table 1 Risk factors associated with mortality among COVID-19 patients
From: D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study
Univariable OR (95% CI) | P value | Multivariable OR (95% CI) | P value | |
|---|---|---|---|---|
Age (years)a | 1.08 (1.03~1.14) | 0.004 | 1.04 (0.98~1.10) | 0.187 |
Female (vs male) | 2.32 (0.83~6.48) | 0.109 | - | - |
Comorbidity present (vsnot present) | ||||
Hypertension | 1.58 (0.58~4.31) | 0.374 | - | - |
Diabetes mellitus | 2.83 (0.92~8.67) | 0.069 | - | - |
SOFA scorea | 2.00 (1.50~2.69) | 0.000 | 1.44 (0.89~2.33) | 0.134 |
qSOFA scorea | 4.47 (2.22~8.99) | 0.000 | 2.43 (0.87~6.77) | 0.091 |
ISTH-DIC score | ||||
0–4 | 1 (ref) | - | ||
≥ 5 | 24.43 (3.77~158.31) | 0.000 | 1.40 (0.05~36.97) | 0.84 |
CURB-65 score | ||||
0–1 | 1 (ref) | - | ||
2 | 7.59 (2.20~26.25) | 0.001 | 1.31 (0.26~6.71) | 0.743 |
≥ 3 | 14.43 (3.89~53.56) | 0.000 | 0.86 (0.09~8.05) | 0.895 |
Lymphocyte count (109/L) | ||||
< 1.0 | 9.85 (2.54~37.80) | 0.001 | 1.94 (0.24~15.57) | 0.533 |
≥ 1.0 | 1 (ref) | - | ||
Alanine aminotransferase (U/L) | ||||
≤ 40 U/L | 1 (ref) | - | - | - |
> 40 U/L | 0.48 (0.13~1.72) | 0.259 | - | - |
eGFR (ml/[min*1.73m2]) | ||||
< 90 | 1.67 (0.60~4.67) | 0.326 | - | - |
≥ 90 | 1 (ref) | - | - | - |
Creatine kinase (U/L) | ||||
≤ 198 | 1 (ref) | - | - | - |
> 198 | 2.18 (0.58~8.25) | 0.250 | - | - |
D-dimer (mg/L) | ||||
< 1 | 1 (ref) | - | 1 (ref) | - |
1–2 | 2.48 (0.15~40.47) | 0.524 | 2.21 (0.12~38.61) | 0.612 |
> 2 | 24.43 (3.16~189.00) | 0.002 | 10.17 (1.10~94.38) | 0.041 |
Anticoagulation therapy | ||||
No | 1 (ref) | - | - | |
Yes | 0.95(0.34~2.67) | 0.93 | - | |